Elizabeth M. Berry-Kravis, MD, PhD
Berry-Kravis
Elizabeth
M
MD, PhD
Associate Professor
Biochemistry,Neurological Sciences,Pediatrics
Rush Medical College,Rush University
1735 West Harrison Street
Suite 718
Chicago, Illinois 60612
1750 West Harrison
15th Floor JELKE
Chicago, Illinois 60612
(312) 942-4036
(312) 942-4168
elizabeth_m_berry-kravis@rush.edu
BS, Chemistry, University of Notre Dame, 1979

PhD, Biochemistry, University of Chicago, 1983

MD, University of Chicago, 1985
Genetic Processes,Mental Disorders,Nervous System Diseases
Gene Transfection,In Situ Hybridization,PCR,si RNA,Western Northern Southern Blotting
Elizabeth Berry-Kravis MD, PhD is a professor of pediatrics, neurology, and biochemistry at Rush University Medical Center. She received a Bachelor's degree in chemistry from the University of Notre Dame in 1979, a PhD in biochemistry in 1983 and MD in 1985 from the University of Chicago. She completed a pediatrics residency in 1987 and pediatric neurology fellowship in 1990, also at the University of Chicago, and moved to Rush University Medical Center in 1992.
 
Dr. Berry-Kravis established the comprehensive Fragile X Clinic and Research Program at Rush in 1992, through which she provides care and support to over 400 patients with fragile X syndrome for management of neurological, medical, and behavioral and genetic issues. Her clinical research projects involve studies of epilepsy and psychopharmacology in fragile X, clinical trials of new promising medications in FXS and development of outcome measures and biomarkers for such trials in the FXS population. She is also involved in research to characterize neurological problems in fragile X-associated tremor/ataxia syndrome (FXTAS) and relate clinical and radiological findings to molecular measures in fragile X carriers. Her laboratory research involves studies of effects of fragile X mental retardation protein (FMRP) on signal transduction mechanisms in neural cells as well as molecular studies aimed at identifying genetic risks and genotype-phenotype relationships in neurological disorders, including Alzheimers disease, Parkinsons disease, vascular dementia, congenital central hypoventilation syndrome and SIDS.
 
At Rush and other Chicago Institutions, Dr. Berry-Kravis lectures in Biochemistry, Pathology, Genetics, Neurobiology and Genetic Counseling courses. She co-directs the Molecular Diagnostics Laboratory at RUSH, which runs molecular tests for diagnosis of numerous genetic conditions including fragile X syndrome. She is on the Advisory Board for both the FRAXA Research Foundation and the National Fragile X Foundation and received the Jarrett Cole Award for clinical work with individuals with fragile X in 2002 and The Hagerman Award for FXTAS research in 2004. Because of the substantial overlap between characteristics of fragile X syndrome and other developmental disorders such as autism, Dr. Berry-Kravis has been heavily involved in work with individuals with a variety of developmental and neurogenetic disorders. She has worked as an advisor to several special education co-ops and has served on the Easter Seals advisory board in Chicago.
 
Research Interests

Fragile X syndrome and Fragile X Tremor/Ataxia syndrome (FXTAS) including clinical management of Fragile X syndrome through large Fragile X clinic– research program includes clinical trials and outcome measures in fragile X; characterization, diagnosis and genetic factors mediating FXTAS; cellular mechanism of neural dysfunction in fragile X; genotype-phenotype studies in Parkinsons disease; risk factors for dementia, and genetic determinants of SIDS and Central Congenital Hypoventilation Syndrome. Clinic specialization is in neurogenetic diseases and genetic neurodevelopmental disorders.

Credentials

American Board of Pediatrics

Certification in neurology with special competence in child neurology, American Board of Psychiatry and Neurology

Selected Articles:

  1. Berry-Kravis E, Lewin F, Wuu J, Leehey M, Hagerman R, Hagerman P and Goetz CG.  Tremor and Ataxia in Fragile X Premutation Carriers:  Blinded Videotape Study.  Ann Neurol 2003;53:616-623.
  2. Berry-Kravis E and Patanos K.  Psychopharmacology in Fragile X Syndrome - Present and Future.  MRDD Research Reviews 2004;10:42-48.
  3. Berry-Kravis E, Zhou L, Rand CM and Weese-Mayer DE.  Congenital Central Hypoventilation Syndrome PHOX2B Mutation and Phenotype.  Am J Respir Crit Care Med 2006;176:1139-1144.
  4. Berry-Kravis E, Krause SE, Block SS, Guter S, Wuu J, Leurgans S, Decle P, Potanos K, Cook E, Sat J, Maino D, Weinberg D, Lara R, Jardini T, Cogswell J, Johson SA and Hagerman R.  Effect of CX516, an AMPA-Modulating Compound, on Cognition and Behavior in Fragile X Syndrome:  A Controlled Trial.  J Child Adole Psycho 2006;16:525-540.
Print Now Close Window